The goal of this observational study is to characterize the epidemiologic, clinical, severity, and therapeutic features of patients with psoriasis treated in Costa Rica between 2024 and 2025. The main questions it aims to answer are:

What are the demographic and clinical characteristics and severity profiles of psoriasis patients?

What treatments are used in routine clinical practice, and how are they associated with disease severity and outcomes?

Patients with psoriasis receiving dermatologic care during the study period will be included. Data will be obtained retrospectively from electronic medical records and clinical registries without intervention or modification of treatment.

Psoriasis is a chronic immune-mediated inflammatory dermatosis with variable severity, systemic associations, and substantial quality-of-life impact. Although multiple topical, phototherapy, systemic, and biologic treatments are available, real-world epidemiologic and therapeutic data in Costa Rica remain limited. This study is a retrospective observational characterization of psoriasis patients treated between 2024 and 2025. Unlike interventional trials evaluating specific drugs or prospective registries of targeted therapies, this study analyzes existing clinical records to describe demographic distribution, clinical subtypes, severity (PASI/BSA/DLQI), comorbidities, and treatment patterns across routine care. It does not introduce therapeutic modifications or standardized follow-up, but reflects real-world management decisions across disease severities. By capturing population-level data on psoriasis presentation and treatment in Costa Rica, the study provides baseline national evidence distinct from drug-specific or interventional psoriasis studies.

Inclusion Criteria:

• Patients evaluated in outpatient clinics during the period 2024-2025.
• Patients receiving systemic therapy and/or phototherapy.
• Patients aged 12 years or older, of any sex.
• Availability of sufficient clinical information to assess psoriasis severity, metabolic comorbidities, atherosclerotic cardiovascular disease, and psoriatic arthritis.
• At least one dermatologic or rheumatologic evaluation recorded in the Electronic Health Record (EHR-EDUS) during the study period.
• Confirmed diagnosis of psoriasis documented in the Electronic Health Record (EHR-EDUS) of Hospital Calderón Guardia.

Exclusion Criteria:

• Clinical records insufficient to evaluate psoriasis severity, comorbidities, or therapeutic profile.
• Patients managed exclusively with topical therapies.
• Duplicate or inconsistent records, preventing accurate patient classification.
• Cutaneous conditions not compatible with psoriasis.

All

The study population comprises adolescents and adults (≥12 years) with a confirmed diagnosis of psoriasis documented in the Electronic Health Record (EHR-EDUS) of Hospital Calderón Guardia who were evaluated in outpatient dermatology or rheumatology clinics between 2024 and 2025. Eligible patients received systemic therapy and/or phototherapy for psoriasis and had sufficient clinical information to assess disease severity, metabolic comorbidities, atherosclerotic cardiovascular disease, and psoriatic arthritis. This hospital-based cohort reflects real-world patients with moderate-to-severe psoriasis managed in specialized care within the Costa Rican public health system during the study period.

According to the protocol.